| |
The biotech industry has truly, at last, sprung back to life… |
| Isomorphic Labs was founded in 2021 as a startup of sorts within a subsidiary of Alphabet (GOOGL) called DeepMind. |
DeepMind gained widespread fame in life sciences in 2020 with its breakthrough release of AlphaFold2 – an artificial intelligence (AI) that could predict the structure of 200 million proteins based only on their amino acid sequences. And it did so with remarkable accuracy, solving one of the grand challenges of life sciences. |
| DeepMind founder Demis Hassabis was awarded the Nobel Prize in Chemistry in 2024 for his work with AlphaFold2. |
| AlphaFold2's release was the catalyst for forming Isomorphic Labs, which was established to commercialize DeepMind's scientific breakthroughs in protein structure prediction. |
| And it laid the foundation for the future of drug design and development… |
| When AI and Biotechnology Collide |
| Isomorphic Labs was also created to provide an economic incentive for the team that developed AlphaFold2 to stick around and keep building upon their work with the potential of an even larger exit via an acquisition or IPO – something we'll certainly be looking for. |
| After DeepMind established Isomorphic Labs, it continued to work on its AI model to make something even more capable for the purpose of drug discovery. The result was AlphaFold3, which was released in the spring of 2024. |
| AlphaFold3 is an even more remarkable breakthrough in that it can accurately predict both the structure of, and interactions of not just proteins, but DNA, RNA, and ligands. |
| Ligands are small molecules that bind to other molecules and are what many drugs are made of. And understanding how a drug molecule binds to a target protein is one of the most critical factors in drug development. |
| |
| Source: Isomorphic Labs |
| It was therefore inevitable that Isomorphic Labs would end up partnering with pharmaceutical companies for the purpose of leveraging AlphaFold3 for commercial purposes and accelerating drug development. |
| That's exactly what happened in January 2024 when Isomorphic announced partnerships with two of the largest pharmaceutical companies in the world |
- Isomorphic announced a deal with Eli Lilly (LLY) to receive $45 million up front with the potential to receive as much as $1.7 billion in milestone payments. The goal is to accelerate the discovery of small-molecule therapeutics against multiple targets.
- Announced on the same day was a deal with Novartis (NVS) whereby Isomorphic received $37.5 million upfront, which is also targeting small molecule therapeutics against three undisclosed targets. Isomorphic also has the potential to receive as much as $1.2 billion in milestone payments as part of the deal.
|
| These were massive deals with almost $3 billion worth of potential economic value to Isomorphic and its largest shareholders – Alphabet and Google Ventures. But the size of the deals is actually far larger… |
| Both the Eli Lilly deal and the Novartis deal have provisions for Isomorphic to earn "up to low double digits on net sales" of any drugs that are commercialized by either company. Said another way, there are likely billions more coming to Isomorphic in the years ahead. |
| Understanding how novel small molecules bind to proteins will increase efficacy and reduce the likelihood of moving drugs with toxicity through either therapeutic pipeline. And it goes without saying that Isomorphic's AI models are capable of research and analysis in days for tasks that have historically taken years. |
| Drug development costs will plummet, and time to market will accelerate. |
| Isomorphic handles the high-probability discovery process with AI, and then Eli Lilly and Novartis take the best candidates through the pre-clinical and clinical trials process (i.e., the wet work). |
| And this week, almost exactly two years from the Eli Lilly and Novartis announcements, Isomorphic announced an even larger deal… |
| Recommended Links
Three New AI Plays for the FASTEST Gains You'll Ever See This coming Wednesday, January 28, at 8 p.m. ET, Jeff Brown is having a special online strategy session he's calling 24-Hour AI Fortunes… Where he will recommend THREE new trades to take advantage of a strange phenomenon… That has delivered gains big enough to turn $10,000 into $101,700… $151,600, and even a mind-blowing $650,000… all in a 24-hour period. Click here to automatically save your seat.
(When you click the link, your email address will automatically be added to Jeff’s guest list.)
This Backdoor Energy Play Beat Gold by 15x Gold has hit all-time highs, breaking above $3,500 for the first time ever – but one little-known energy play has seen 15x the return since the start of this year. It's all thanks to the incredible energy demands AI is putting on our country… No, it's not nuclear or oil… and it's got nothing to do with renewable energy. It's a bull market hiding in plain sight, and 40-year Wall Street veteran Larry Benedict has found one company at the heart of it all. It's the centerpiece of his full play for these unpredictable markets, with incredible upside potential. Click here for full details on this developing story.
| |
| The Future of Drug Design |
| Isomorphic will be teaming up with Johnson & Johnson (JNJ). While the terms of the deal were not disclosed, the breadth of the partnership is wider than the previous two deals. |
| The partnership is both multi-target and cross-modality in scope. The modalities will include small molecules, antibodies, peptides, and molecular glues, which is a technique that uses small molecules to force two proteins to bind together in order to get rid of unwanted proteins in the body. |
| Isomorphic's Chief Research Officer had an interesting quote about the deal: |
0 التعليقات:
إرسال تعليق